Mitsubishi Tanabe Pharma America Presents ND0612 Data for Parkinson's Disease at PSG Meeting
核心洞察
Mitsubishi Tanabe Pharma America (搜索) (MTPA) presented data on ND0612, an investigational continuous subcutaneous infusion of levodopa/carbidopa, at the Parkinson Study Group (PSG) meeting.
The presentations included three-year outcomes from the Phase 2b BeyoND study, evaluating the safety and efficacy of ND0612 in Parkinson's patients with motor fluctuations.
MTPA also presented a characterization of infusion site reactions (ISRs) associated with ND0612 treatment, based on integrated safety data from clinical studies.
Mitsubishi Tanabe Pharma America (搜索) (MTPA) presented new data on its investigational drug ND0612, a 24-hour continuous subcutaneous infusion of liquid levodopa/carbidopa (LD/CD) for Parkinson's disease (搜索), at the 2024 Annual Meeting of the Parkinson Study Group (PSG) in Nashville, Tennessee. The presentations highlighted findings from the open-label Phase 2b BeyoND study and characterized infusion site reactions associated with ND0612.
The BeyoND study (NCT02726386) evaluated the long-term safety and efficacy of ND0612 over three years in Parkinson's disease (搜索) patients experiencing motor fluctuations. One presentation focused on these three-year outcomes. The other presentation detailed the characterization of infusion site reactions (ISRs) reported during ND0612 treatment across various clinical studies.
ND0612: A Novel Approach to Levodopa Delivery
ND0612 is an investigational drug-device combination therapy designed to provide a continuous, 24-hour subcutaneous infusion of levodopa and carbidopa. This approach aims to mitigate motor fluctuations, a common and debilitating symptom in Parkinson's disease (搜索), by delivering a stable and consistent dose of levodopa.
Parkinson's Disease and the Need for Continuous Levodopa Delivery
Parkinson's disease (搜索) is a progressive neurodegenerative disorder affecting millions worldwide. Levodopa, a precursor to dopamine, remains the gold standard treatment for managing motor symptoms. However, oral levodopa therapy can lead to fluctuations in drug levels, resulting in "on-off" periods and dyskinesias. Continuous levodopa delivery systems, like ND0612, seek to address these limitations by providing a more stable therapeutic effect.
MTPA's Commitment to Parkinson's Disease
"This ongoing research is driven by our passion to support the Parkinson's disease (搜索) community and continue investigating areas of significant unmet needs for patients," said Gustavo A. Suarez Zambrano, M.D., Vice President of Medical Affairs, MTPA. The company's presentations at the PSG meeting underscore its dedication to advancing Parkinson's disease treatment and improving patient outcomes.